Starting a GLP-1 to manage type 2 diabetes was associated with a higher chance of developing NAION within a year, based on a study using historical data of over 520,000 patients
The agencys notice today reaffirms that compounding is meant to be a rare and limited exception to FDAs gold-standard drug approval framework, a Novo spokesperson said
(PRIP Substack, Jan 4, 2026) The ChinaSwitzerland FTA, mentioned by generic drug makers, took effect in 2014
Cardiovasc Diabetol 2018;17(1):126
Recent reports of unexpected pregnancies while using GLP-1 medications are often referred to as Ozempic babies. In a previous article, we explored why these pregnancies occur and what they may mean for patients considering treatment
You can have an increase in hunger when you stop taking it, which could result in weight gain